Physician profile
Adriana C Rossi
NPI 1386847721
$268,717.30
in general payments reported to CMS, 2019-2025
21 companies · $31K in 2025
The $31K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $18K · 2021: $20K · 2022: $53K · 2023: $66K · 2024: $35K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $84K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Travel and Lodging: $12K · Food and Beverage: $2,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $83,921.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,748.00 |
| Travel and Lodging | $12,247.21 |
| Food and Beverage | $2,715.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $45,909.18 | 2019-2025 | Carvykti, Tecvayli, Darzalex |
| Genzyme Corporation | $43,721.85 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $41,864.30 | 2021-2025 | Clonoseq |
| Celgene Corporation | $34,019.99 | 2019-2023 | Pomalyst |
| Sanofi-Aventis U.S. LLC | $30,289.51 | 2023-2024 | |
| Janssen Global Services, LLC | $24,136.54 | 2019-2023 | Carvykti |
| Glaxosmithkline, LLC. | $17,355.00 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $10,085.63 | 2022-2024 | Xpovio |
| Kite Pharma, INC. | $8,567.12 | 2025 | Yescarta |
| Janssen Scientific Affairs, LLC | $3,992.83 | 2019-2024 | Carvykti, Talvey, Tecvayli |
| Legend Biotech USA INC. | $3,569.47 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $2,969.07 | 2022-2025 | |
| Secura Bio, INC. | $1,601.50 | 2019 | |
| Amgen INC. | $206.10 | 2019 | |
| Janssen Research & Development, LLC | $197.25 | 2019-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $127.01 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $44.41 | 2019 | |
| Abbvie INC. | $22.84 | 2024 | |
| Akcea Therapeutics, INC. | $19.80 | 2019 | |
| Pfizer INC. | $17.90 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.